Skip to main content

Advertisement

Log in

Ileal perforation induced by acute radiation injury under gefitinib treatment

  • Case Report
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Enteritis is one of the side effects of radiotherapy to the abdominal cavity. Radiation enteritis involves damage to mucous membranes in the acute phase and to stromal tissues in the late phase. Perforation of the intestine tends to occur in the late phase, and rarely in the acute phase. However, we describe here a case of intestinal perforation occurring in the acute phase after irradiation in a patient who received gefitinib treatment. Gefitinib, one of the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), is widely used to treat non-small cell lung cancer (NSCLC) patients, but is simultaneously known to inhibit wound healing. We suspect that gefitinib may affect regeneration of the small intestinal mucosa injured by irradiation. A 76-year-old woman had NSCLC with metastases to the 5th lumbar, sacral, and right iliac bones. To control the pain from bone metastasis, anterior-posterior opposing portal irradiation (total 35 Gy) was started, and was completed over 22 days. On day 25 after starting radiotherapy, the patient began to take gefitinib. On day 35, she presented with acute peritonitis, and an emergency laparotomy was performed. The terminal ileum was affected by radiation enteritis and there were two pin-hole perforations. In the surgical specimen, no cancerous lesions were detected, and immunohistochemical staining of phosphorylated EGFR (pEGFR) was negative. pEGFR has an important role in mucous membrane repair after irradiation. Intestinal perforation in the acute phase of radiation enteritis may be associated with impaired mucosal repair mechanisms due to the use of an EGFR-TKI such as gefitinib, as evidenced by the absence of pEGFR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Kavanagh BD, Pan CC, Dawson LA et al (2010) Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 76:S101–S107

    Article  PubMed  Google Scholar 

  2. Yamashita H, Nakagawa K, Tago M et al (2006) Small bowel perforation without tumor recurrence after radiotherapy for cervical carcinoma: report of seven cases. J Obstet Gynaecol Res 32:235–242

    Article  PubMed  Google Scholar 

  3. Mitsudomi T, Kosaka T, Yatabe Y (2006) Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 11:190–198

    Article  PubMed  CAS  Google Scholar 

  4. Yin J, Xu K, Zhang J et al (2007) Wound-induced ATP release and growth receptor activation in epithelial cells. J Cell Sci 120:815–825

    Article  PubMed  CAS  Google Scholar 

  5. Block ER, Klarlund JK (2008) Wounding sheets of epithelial cells activates the epidermal growth factor receptor through distinct short- and long-range mechanisms. Mol Biol Cell 7:4909–4917

    Article  Google Scholar 

  6. Jones MK, Tomikawa M, Mohajer B et al (1999) Gastrointestinal mucosal regeneration: role of growth factors. Front Biosci 4:303–309

    Google Scholar 

  7. Kitagawa K, Hamada Y, Kato Y et al (2004) Epidermal growth factor and interleukin-1β synergistically stimulate the production of nitric oxide in rat intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 287:1188–1193

    Google Scholar 

  8. Myhre GM, Toruner M, Abraham S et al (2004) Metalloprotease disintegrin-mediated ectodomain shedding of EGFR ligands promotes intestinal epithelial restitution. Am J Physiol Gastrointest Liver Physiol 287:1213–1219

    Article  Google Scholar 

  9. Nakagawa K, Tamura T, Negoro S et al (2003) Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14:922–930

    Article  PubMed  CAS  Google Scholar 

  10. Zhuang HQ, Sun J, Yuan ZY et al (2009) Radiosensitizing effects of gefitinib at administration times in vitro. Cancer Sci 100:1520–1525

    Article  PubMed  CAS  Google Scholar 

  11. Taira N, Doihara H, Oota T et al (2006) Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro. Acta Med Okayama 60:25–34

    PubMed  CAS  Google Scholar 

  12. Gow CH, Chien CR, Chang YL et al (2008) Radiotherapy in lung adenocarcinoma with brain metastasis: effects of activating epidermal growth factor mutations on clinical response. Clin Cancer Res 14:162–168

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

Takayuki Muraoka and the other co-authors have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Takayuki Muraoka.

About this article

Cite this article

Muraoka, T., Tsukuda, K., Toyooka, S. et al. Ileal perforation induced by acute radiation injury under gefitinib treatment. Int J Clin Oncol 16, 774–777 (2011). https://doi.org/10.1007/s10147-011-0249-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-011-0249-8

Keywords

Navigation